Standard BioTools Inc. (LAB) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
LAB Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Standard BioTools Inc. (LAB) trades at a price-to-earnings ratio of -5.1x, with a stock price of $1.02 and trailing twelve-month earnings per share of $0.20.
The current P/E is 211% below its 5-year average of 4.6x. Over the past five years, LAB's P/E has ranged from a low of 4.6x to a high of 4.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, LAB trades at a 123% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, LAB trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LAB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LAB P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $22B | 26.0 | 6.15Best | +171%Best | |
| $173B | 26.2 | 12.41 | +7% | |
| $121B | 34.0 | - | -5% | |
| $7B | 9.1Lowest | - | +143% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
LAB Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $0.92 | $0.20 | 4.6x | +0% |
Average P/E for displayed period: 4.6x
See LAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LAB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLAB — Frequently Asked Questions
Quick answers to the most common questions about buying LAB stock.
Is LAB stock overvalued or undervalued?
LAB trades at -5.1x P/E, below its 5-year average of 4.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does LAB's valuation compare to peers?
Standard BioTools Inc. P/E of -5.1x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is LAB's PEG ratio?
LAB PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.